817 / 1708
Conclusions
•
Omission of radiotherapy in Group II and Group III
rhabdomyosarcoma results in higher local failure and in some
sites can impact on survival
•
Current trials in North America and Europe are looking at dose
escalation up to 59.4 Gy for children with high risk for local
failure
•
It is unclear whether radiotherapy to metastatic sites improve
overall outcome of patients